APOE and Alzheimer disease: Cummings et al. [10] showed that for patients with mild-to-moderate AD, bexarotene was able to reduce brain Aβ42 levels in noncarriers of apoE4, though they demonstrated that the drug was unable to reduce Aβ42 in apoE4 carriers.